Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-10-30
2009-08-25
Seaman, D. Margaret (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
07579486
ABSTRACT:
The present invention relates to metalloprotein inhibitors comprising:a. an organic substituent and at least one zinc binding group (ZBG) covalently attached thereto; orb. a ZBG substituted by a side chain wherein the ZBG is of formula (I):wherein X is O or S and each R1, R2, R3, and R4is individually hydrogen or an organic radical. The metalloprotein inhibitors are useful for preventing or treating a pathological disease, condition, or symptom that is associated with pathological metalloprotein activity and/or that is alleviated by inhibition of said activity.
REFERENCES:
patent: 4585780 (1986-04-01), Hider et al.
patent: 5981496 (1999-11-01), Cohen et al.
patent: 6552073 (2003-04-01), Leblanc et al.
patent: 6825204 (2004-11-01), Liu
patent: 6932960 (2005-08-01), Liu
patent: 2004/0063673 (2004-04-01), Johnson
patent: 2008/0161362 (2008-07-01), Puerta et al.
patent: 1006112 (2000-06-01), None
patent: WO-2004110442 (2004-12-01), None
patent: WO-2005110399 (2005-11-01), None
patent: WO-2006028523 (2006-03-01), None
patent: WO-2006028523 (2006-03-01), None
Dilsiz Aytemeir et al. Turk.J.Chem. 2003, 27, 757-764.
Shapiro et al. Eur Respir J 2003; 22:30S-32S.
Belonosov et al. STN Accession No. 1952:67070 Document No. 46:67070. Abstract of Zhurnal Prikladnoi Khimii (Sankt-Peterburg, Russian Federation) (1951), 24, 113-16.
Hoeksema et. al STN Accession No. 1979:575314 Document No. 91:175314 Abstract of Journal of Antibiotics (1979), 32(7), 773-6.
“U.S. Appl. No. 11/568,505, Preliminary Amendment mailed Oct. 30, 2006”, 11 pgs.
“U.S. Appl. No. 11/568,505, Supplemental Preliminary Amendment filed Oct. 26, 2007”, 9 pgs.
“U.S. Appl. No. 11/568,505, Second Preliminary Amendment filed Aug. 20, 2007”, 10 pgs.
“European Patent Applicatiion No. 05818191.8, Communication Pursuant to Article 96(2)EPC mailed Jul. 5, 2007”, 4 pgs.
“PCT Application No. PCT/US2005/014747, International Search Report mailed Mar. 10, 2006”, 6 pgs.
“PCT Application No. PCT/US2005/014747, Written Opinion of the Searching Authority (Mar. 10, 2006)”, 6 pgs.
Atkinson, J. G., et al., “Kojic Amine—A Novel Gamma-Aminobutyric Acid Analogue”,Journal of Medicinal Chemistry, 22 (1), (1979),99-106.
Beckett, R. P., et al., “Matrix Metalloproteinase Inhibitors 1998”,Expert Opinion on Therapeutic Patents, 8(3), (Mar. 1998),259-282.
Beckett, R. P., et al., “Recent Advances in Matrix Metalloproteinase Inhibitor Research”,Drug Discovery Today, 1(1), (Jan. 1996),16-26.
Brinckerhoff, C. E., et al., “Matrix Metalloproteinases: A Tail of a Frog That Become a Prince”,Nature Reviews—Molecular Cell Biology, 3, (Mar. 2002),207-214.
Chen, L. , et al., “Crystal Structure of the Stromelysin Catalytic Doman at 2.0 A Resolution: Inhibitor-Induced Conformational Changes”,Journal of Molecular Biology, 293, (1999),545-557.
Dilsiz Aytemir, M. , et al., “Synthesis and Evaluation of Antimicrobial Activity of New 3-hydroxy-6-methyl-4-xox-4h-pyran-2-carbox amide derivatives”,Turkish Journal of Chemistry, vol. 27 (6), (2003),757-764.
Hajduk, P. J., et al., “NMR-Based Modification of Matrix Metalloproteinase Inhibitors With Improved Bioavailability”,Journal of Medicinal Chemistry, 45, (2002),5628-5639.
Jacobsen, F. E., et al., “Using Model Complexes to Augment and Advance Metalloproteinase Inhibitor Design”,Inorganic Chemistry, 43, (2004),3038-3047.
Lewis, J. A., et al., “Metal Complexes of the trans-Influencing Ligand Thiomaltol”,Inorganic Chemistry, 42(23), (2003),7455-7459.
Lim, S. , et al., “Competitive Inhibition of Tyrosinase by 5-Hydroxy-2-phenylalanylaminomethyl-4-pyron”, Yakhak Hoechi, vol. 44 (3), (2000),279-282.
Opdenakker, G. , et al., “Cytokines and Proteases in Invasive Processes: Molecular Similarities Between Inflammation and Cancer”,Cytokine, 4(4), (Jul. 1992),251-258.
Overall, C. M., et al., “Strategies for NMP Inhibition in Cancer: Innovations for the Post-Trial Era”,Nature Reviews, Cancer, 2, (Sep. 2002),657-672.
Puerta, D. T., et al., “A Bioinorganic Perspective on Matrix Mettaloproteinase Inhibition”,Current Topics in Medicinal Chemistry, 4, (2004),1551-1573.
Puerta, D. T., et al., “Elucidating Drug-Metalloprotein Interactions with Tris(pyrazolyl)borate Model Complexes”,Inorganic Chemistry, 41(20), (2002),5075-5082.
Puerta, D. T., et al., “Examination of Novel Zinc-Binding Groups for Use in Matrix Metalloproteinase Inhibitors”,Inorganic Chemistry, 42, (2003),3423-3430.
Puerta, D. T., et al., “From Model Complexes to Metalloprotein Inhibition: A Synergistic Approach to Structure-Based Drug Discovery”,Angewandte Chemie International Edition, 42(32), (2003),3772-3774.
Puerta, D. T., et al., “New Beginnings for Matrix Metalloproteinase Inhibitors: Identification of High-Affinity Zinc-Binding Groups”,Journal of the American Chemical Society, 126(27), (2004),8388-8389.
Puerta, D. T., “Potent, Selective Pyrone-Based Inhibitors of Stromelysin-I”,J. Am. Chem. Soc., 127 (41), (2005), 14148-14149.
Skiles, J. W., et al., “The Design, Structure, and Therapeutic Application of Matrix Metalloproteinase Inhibitors”,Current Medicinal Chemistry, 8(4), (2001),425-474.
Storr, T. , et al., “Vanadyl-Thiazolidinedione Combination Agents for Diabetes Therapy”,Bioconjugate Chem. 14 (1), (2003),212-221.
Whittaker, M. , et al., “Design and Therapeutic Application of Matrix Metalloproteinase Inhibitors”,Chem. Rev., 99, (1999),2735-2776.
Whittaker, M. , et al., “Matrix Metalloproteinases and Their Inhibitors—Current Status and Future Challenges”,Celltransmissions, 17(1), (2001),3-14.
Wojtowicz-Praga, S. M., et al., “Matrix Metalloproteinase Inhibitors”,Investigational New Drugs, 15, (1997),61-75.
Woods, L. L., “Mannich Bases from Kojic Acid and Aryl Amines”,J of the American Chemistry Society, vol. 68, (1946),2744-2745.
Yeh, L.-A. , et al., “Inhibition of Metalloproteinase by Futoenone Derivatives”,Biorganic&Medicinal Chemistry Letters, 5(15), (Aug. 1995),1637-1642.
Cohen Seth M.
Lewis Jana A.
Puerta David T.
Chandrakumar Nizal S
Regents of the University of California, San Diego
Schwegman Lundberg & Woessner, P.A.
Seaman D. Margaret
LandOfFree
Metalloprotein inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Metalloprotein inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Metalloprotein inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4106404